Indium (111in)-Dtpa Curium Netherlands Bv (Pentetic Acid, Indium (111in) Pentetate)

The drug combines the gamma‑emitting radionuclide Indium‑111 with the chelating agent pentetate (DTPA). After intrathecal injection, the complex spreads throughout the cerebrospinal fluid, and its emitted gamma radiation is captured by imaging equipment to produce detailed pictures of CSF flow and potential leak sites.

The administered activity is determined by the prescribing physician based on the patient’s weight, the imaging protocol, and regulatory guidelines. Dosage is individualized and should be prepared and administered by qualified nuclear medicine personnel.

Use in pregnancy is only considered when the diagnostic benefit outweighs potential fetal radiation risk, and it should be avoided if possible. Limited data exist for breastfeeding; the drug may be excreted in milk, so cessation of nursing is generally recommended until the tracer is cleared.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Indium‑111 pentetate offers a longer half‑life and gamma emission suitable for high‑resolution imaging, compared with shorter‑lived agents like Technetium‑99m DTPA. Its chelated form provides stable distribution in CSF, making it a preferred choice for detailed leak localization when longer imaging windows are required.

The product should be stored at 2‑8 °C, protected from light, and kept in its original container to maintain sterility. Do not freeze or shake the vial, and handle it using radiation safety protocols to limit exposure to personnel.

The radiopharmaceutical is administered by a trained professional via intrathecal injection, typically through a lumbar puncture. Proper aseptic technique and precise dosing are essential to ensure accurate imaging and patient safety.

Serious risks include severe allergic reactions (anaphylaxis), significant hypotension, rare seizures, and radiation‑induced tissue injury. Immediate medical attention is required if any of these events occur during or after the procedure.

Patients with known hypersensitivity to DTPA or other chelating agents, those with uncontrolled bleeding disorders, and individuals for whom intrathecal procedures are contraindicated should not receive this radiopharmaceutical. Additionally, it should be avoided in pregnant women unless the diagnostic benefit justifies the risk.